Cero Therapeutics Holdings Stock Performance
| CEROW Stock | 0.01 0 14.29% |
CERo Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -2.91, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning CERo Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, CERo Therapeutics is expected to outperform it. Use CERo Therapeutics value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on CERo Therapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, CERo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | CERo Therapeutics, Inc. Provides Corporate Update - Yahoo Finance | 10/21/2024 |
2 | CERo Therapeutics Stock Sees Significant Climb After Revealing Ovarian Cancer Data - TipRanks | 11/12/2024 |
3 | CERo Therapeutics Holdings, Inc. Appoints Chris Ehrlich CEO - Marketscreener.com | 12/06/2024 |
4 | Cero Therapeutics holdings sees 400,456 in stock sales by YK Bioventures - Investing.com | 12/13/2024 |
| Begin Period Cash Flow | 42.1 K | |
| Free Cash Flow | -1519.60 |
CERo |
CERo Therapeutics Relative Risk vs. Return Landscape
If you would invest 1.20 in CERo Therapeutics Holdings on September 22, 2024 and sell it today you would lose (0.30) from holding CERo Therapeutics Holdings or give up 25.0% of portfolio value over 90 days. CERo Therapeutics Holdings is currently producing 4.7524% returns and takes up 36.2393% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than CERo, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CERo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CERo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CERo Therapeutics Holdings, and traders can use it to determine the average amount a CERo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1311
| Best Portfolio | Best Equity | CEROW | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 36.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.75 actual daily | 94 94% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average CERo Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CERo Therapeutics by adding it to a well-diversified portfolio.
CERo Therapeutics Fundamentals Growth
CERo Stock prices reflect investors' perceptions of the future prospects and financial health of CERo Therapeutics, and CERo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CERo Stock performance.
| Return On Asset | -0.45 | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (2.27) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M | ||||
About CERo Therapeutics Performance
Evaluating CERo Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if CERo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CERo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.87) | (0.82) |
Things to note about CERo Therapeutics performance evaluation
Checking the ongoing alerts about CERo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CERo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CERo Therapeutics is way too risky over 90 days horizon | |
| CERo Therapeutics has some characteristics of a very speculative penny stock | |
| CERo Therapeutics appears to be risky and price may revert if volatility continues | |
| CERo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| CERo Therapeutics Holdings was previously known as Phoenix Biotech Acquisition and was traded on NASDAQ Exchange under the symbol PBAXW. | |
| Net Loss for the year was (2.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| CERo Therapeutics generates negative cash flow from operations | |
| CERo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cero Therapeutics holdings sees 400,456 in stock sales by YK Bioventures - Investing.com |
- Analyzing CERo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CERo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CERo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CERo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CERo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CERo Therapeutics' stock. These opinions can provide insight into CERo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.